A liquid biopsy is an emerging tool for the diagnosis of cancer disease nowadays. The liquid biopsy involves collecting samples and analysing tumours in the blood to diagnose cancer disease in the human body. Liquid biopsy assists medical practitioners as a source of genomic and proteomic knowledge in cancer patients by early detection of circulating tumour cells, DNA and extracellular vesicles. Currently, liquid biopsy plays a critical role in accelerating and implementing accurate oncology in clinical settings by leading to an improved understanding of tumour heterogeneity and allowing for dynamic control of reactions to care and variations in genomics. According to Renub Research analysis, Global Liquid Biopsy Market is expected to be US$ 3.1 Billion by 2026.
Follow the Link for Report Customization: https://www.renub.com/liquid-biopsy-market-p.php
The major growth drivers of liquid biopsies are that while extracting the tissue sample from the human body is much pain-free, it substitutes the pain associated with the procedure. Besides, liquid biopsy is very accurate in detecting tumour cells in the blood of cancer patients. Due to the low sensitivity of liquid biopsy, it acts as the restraint factor in the market's growth.
The key players play an essential role in the liquid biopsy market's growth by launching innovative products. In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. The COVID-19 effect in the liquid biopsy market has been harsh because all patients are taking therapies to treat cancer; since they have a weak immune system, and they are less prone to fight with coronavirus diseases.
Renub Research report titled “Liquid Biopsy Market Global Forecast by Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer & Others), Product (Kits & Consumables, Instruments and Services), Sample (Plasma/Serum, Urine & Others), Circulating Biomarkers (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) & Exosomes), Clinical Application (Monitoring, Theranostics, Prognosis & Screening), Regions (Europe, North America, Latin America, Asia-Pacific and Middle East/Africa), Companies (Roche Diagnostics, Thermo Fisher Scientific Inc., Biocept Inc., Bio-Rad Laboratories Inc., Genomic Health, Biocartis, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories)” provides a detailed analysis of Global Liquid Biopsy Industry.
Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=liquid-biopsy-market-p.php
1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
1. Kits & Consumables
By Circulating Biomarkers
1. Circulating Tumor Cells (CTCs)
2. Circulating Tumor DNA (ctDNA)
3. Extracellular Vesciles
By Clinical Application
1. North America
4. Latin America
5. Middle East/Africa
All the 9 Companies Studied in the Report have been Studied from three Points
• Company Overview
• Recent Development
• Financial Insight
1. Thermo Fisher Scientific Inc.
2. Roche Diagnostics
3. Bio-Rad Laboratories Inc.
4. Biocept Inc.
6. Myriad Genetics, Inc.
7. Genomic Health
8. NeoGenomics Laboratories
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building and Construction, & Agriculture. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: [email protected]
Follow on Linkedin: https://www.linkedin.com/company/renub-research